JAZZ
Jazz Pharmaceuticals plc
NASDAQ · IEHealthcareBiotechnology
$243.47-1.64%
Price as of Jul 20, 2026
JAZZ financials
Jazz Pharmaceuticals plc financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B |
| Cost of revenue | $503.3M | $445.7M | $435.6M | $540.5M |
| Gross profit | $3.8B | $3.6B | $3.4B | $3.1B |
| Operating expenses | $3.5B | $2.9B | $2.8B | $3.2B |
| Operating income | $224.4M | $716.6M | $578.6M | -$65.5M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M |
| EBITDA | $108.5M | $1.5B | $1.4B | $1.5B |
| Basic EPS | $-5.84 | $9.06 | $6.55 | $-3.58 |
| Diluted EPS | $-5.84 | $8.65 | $6.10 | $-3.58 |
| Balance sheet | ||||
| Cash & equivalents | $1.4B | $2.4B | $1.5B | $881.5M |
| Total assets | $11.7B | $12.0B | $11.4B | $10.8B |
| Total liabilities | $7.3B | $7.9B | $7.7B | $7.7B |
| Stockholders’ equity | $4.3B | $4.1B | $3.7B | $3.1B |
| Total debt | $5.4B | $6.2B | $5.8B | $5.8B |
| Net debt | $4.0B | $3.7B | $4.3B | $4.9B |
| Cash flow | ||||
| Operating cash flow | $1.4B | $1.4B | $1.1B | $1.3B |
| Capital expenditure | -$209.8M | -$48.1M | -$24.0M | -$498.2M |
| Free cash flow | $1.1B | $1.3B | $1.1B | $773.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$125.0M | -$311.4M | -$269.8M | -$54.0K |